Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation-positive NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01167244
What this trial is testing

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 11
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Testing effectiveness (Phase 2)Study completedNCT02804776
What this trial is testing

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Who this might be right for
Non-small Cell Lung Cancer
National Cancer Centre, Singapore 15
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07710612
What this trial is testing

ABSK043 Combined With Osimertinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Abbisko Therapeutics Co, Ltd 72
Testing effectiveness (Phase 2)UnknownNCT05326425
What this trial is testing

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Who this might be right for
Lung Neoplasms
Jin Hyoung Kang 40
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Testing effectiveness (Phase 2)Looking for participantsNCT07538804
What this trial is testing

Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 294
Testing effectiveness (Phase 2)Study completedNCT01530334
What this trial is testing

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment

Who this might be right for
Lung Cancer
AstraZeneca 61
Not applicableNot Yet RecruitingNCT07686185
What this trial is testing

A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.

Who this might be right for
Non-Small Cell Lung CancerAdjuvant Therapy
First Affiliated Hospital of Guangxi Medical University 500
Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Not applicableUnknownNCT06174857
What this trial is testing

Efficacy of Osimertinib in Patients With Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT07304739
What this trial is testing

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 383
Testing effectiveness (Phase 2)UnknownNCT03720873
What this trial is testing

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

Who this might be right for
EGFR Gene Mutation
Fujian Cancer Hospital 90
Not applicableUnknownNCT04909073
What this trial is testing

Observational Study of Afatinib 30 mg Daily

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor Mutation
National University Hospital, Singapore 69
Not applicableStudy completedNCT04155541
What this trial is testing

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

Who this might be right for
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Pfizer 40
Not applicableUnknownNCT03071705
What this trial is testing

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small Cell AdenocarcinomaTyrosine Kinase MutationEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico 120
Not applicableUnknownNCT04391283
What this trial is testing

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Who this might be right for
Carcinoma, Non-Small-Cell Lung
First Affiliated Hospital of Zhejiang University 500
Early research (Phase 1)UnknownNCT05826483
What this trial is testing

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Who this might be right for
Malignant Tumor of LungPoor Performance Status
Guangzhou Institute of Respiratory Disease 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07789444
What this trial is testing

Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets

Who this might be right for
Non-Small Cell Lung CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Xiaorong Dong 53
Next Page